1. Antiangiogenic effects of PI3K inhibitor NVP-BKM120.
Antiangiogenic effects of PI3K inhibitor NVP-BKM120. A, gross pathologic images of an untreated tumor (left), a tumor treated for 2 weeks (middle), and a tumor treated for 6 weeks (right) with NVP-BKM120 at 50 mg/kg/d via gavage. IHC to detect CD31 in an untreated tumor (B), the center of a tumor treated for 6 weeks (C), and the tumor capsule of a mammary tumor treated for 6 weeks (D). E, determination of the Chalkley score to quantify CD31 staining. IHC with anti-CD31 antibodies was conducted in pretreatment biopsies and in tumor specimens from mice at the time of tumor progression.
Ashish Juvekar et al. Cancer Discovery 2012;2:
©2012 by American Association for Cancer Research